50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,705.89 (+0.34%)
DOW   29,581.62 (-0.03%)
QQQ   279.04 (+1.28%)
AAPL   153.45 (+2.01%)
MSFT   240.96 (+1.28%)
META   140.72 (+0.22%)
GOOGL   99.70 (+0.97%)
AMZN   116.20 (+2.13%)
TSLA   283.21 (+2.86%)
NVDA   125.84 (+0.54%)
NIO   18.27 (+3.57%)
BABA   80.72 (+2.44%)
AMD   68.43 (+0.69%)
T   15.94 (-0.44%)
MU   49.87 (-0.46%)
CGC   2.93 (+3.17%)
F   12.28 (-0.24%)
GE   65.79 (+1.92%)
DIS   100.22 (+0.72%)
AMC   7.89 (-1.25%)
PYPL   88.06 (+1.25%)
PFE   44.16 (+0.18%)
NFLX   231.17 (+2.10%)
S&P 500   3,705.89 (+0.34%)
DOW   29,581.62 (-0.03%)
QQQ   279.04 (+1.28%)
AAPL   153.45 (+2.01%)
MSFT   240.96 (+1.28%)
META   140.72 (+0.22%)
GOOGL   99.70 (+0.97%)
AMZN   116.20 (+2.13%)
TSLA   283.21 (+2.86%)
NVDA   125.84 (+0.54%)
NIO   18.27 (+3.57%)
BABA   80.72 (+2.44%)
AMD   68.43 (+0.69%)
T   15.94 (-0.44%)
MU   49.87 (-0.46%)
CGC   2.93 (+3.17%)
F   12.28 (-0.24%)
GE   65.79 (+1.92%)
DIS   100.22 (+0.72%)
AMC   7.89 (-1.25%)
PYPL   88.06 (+1.25%)
PFE   44.16 (+0.18%)
NFLX   231.17 (+2.10%)
S&P 500   3,705.89 (+0.34%)
DOW   29,581.62 (-0.03%)
QQQ   279.04 (+1.28%)
AAPL   153.45 (+2.01%)
MSFT   240.96 (+1.28%)
META   140.72 (+0.22%)
GOOGL   99.70 (+0.97%)
AMZN   116.20 (+2.13%)
TSLA   283.21 (+2.86%)
NVDA   125.84 (+0.54%)
NIO   18.27 (+3.57%)
BABA   80.72 (+2.44%)
AMD   68.43 (+0.69%)
T   15.94 (-0.44%)
MU   49.87 (-0.46%)
CGC   2.93 (+3.17%)
F   12.28 (-0.24%)
GE   65.79 (+1.92%)
DIS   100.22 (+0.72%)
AMC   7.89 (-1.25%)
PYPL   88.06 (+1.25%)
PFE   44.16 (+0.18%)
NFLX   231.17 (+2.10%)
S&P 500   3,705.89 (+0.34%)
DOW   29,581.62 (-0.03%)
QQQ   279.04 (+1.28%)
AAPL   153.45 (+2.01%)
MSFT   240.96 (+1.28%)
META   140.72 (+0.22%)
GOOGL   99.70 (+0.97%)
AMZN   116.20 (+2.13%)
TSLA   283.21 (+2.86%)
NVDA   125.84 (+0.54%)
NIO   18.27 (+3.57%)
BABA   80.72 (+2.44%)
AMD   68.43 (+0.69%)
T   15.94 (-0.44%)
MU   49.87 (-0.46%)
CGC   2.93 (+3.17%)
F   12.28 (-0.24%)
GE   65.79 (+1.92%)
DIS   100.22 (+0.72%)
AMC   7.89 (-1.25%)
PYPL   88.06 (+1.25%)
PFE   44.16 (+0.18%)
NFLX   231.17 (+2.10%)
NASDAQ:KALA

Kala Pharmaceuticals - KALA Stock Forecast, Price & News

$0.24
-0.02 (-6.92%)
(As of 09/26/2022 10:17 AM ET)
Add
Compare
Today's Range
$0.23
$0.24
50-Day Range
$0.15
$0.34
52-Week Range
$0.25
$3.06
Volume
2,284 shs
Average Volume
1.64 million shs
Market Capitalization
$17.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.38

Kala Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
450.0% Upside
$1.38 Price Target
Short Interest
Healthy
3.49% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.35
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$3,918 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.77) to ($0.60) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars

Medical Sector

243rd out of 1,069 stocks

Pharmaceutical Preparations Industry

99th out of 533 stocks

KALA stock logo

About Kala Pharmaceuticals (NASDAQ:KALA) Stock

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.

Receive KALA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

KALA Stock News Headlines

Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium
The soaring demand for lithium is driven by worldwide demand for electric vehicles (EVs). Lithium is ideal for electric cars. It's lightweight, stores lots of energy and is rechargeable. Sales of EVs are expected to increase 10-fold by 2030 and estimates are that 1 in 2 cars sold will be electric by 2040.
Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium
The soaring demand for lithium is driven by worldwide demand for electric vehicles (EVs). Lithium is ideal for electric cars. It's lightweight, stores lots of energy and is rechargeable. Sales of EVs are expected to increase 10-fold by 2030 and estimates are that 1 in 2 cars sold will be electric by 2040.
Kala Pharmaceuticals Inc Stock News
Why Kala Pharmaceuticals Shares Are Rising Today
What 4 Analyst Ratings Have To Say About Kala Pharmaceuticals
Recap: Kala Pharmaceuticals Q1 Earnings
What Wall Street expects from Kala Pharmaceuticals's earnings
See More Headlines
Receive KALA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

KALA Company Calendar

Last Earnings
8/11/2022
Today
9/26/2022
Next Earnings (Estimated)
11/21/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KALA
Employees
192
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$1.38
High Stock Price Forecast
$2.00
Low Stock Price Forecast
$0.75
Forecasted Upside/Downside
+484.4%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-142,600,000.00
Net Margins
-1,628.91%
Pretax Margin
-1,628.91%

Debt

Sales & Book Value

Annual Sales
$11.24 million
Book Value
$0.26 per share

Miscellaneous

Free Float
62,717,000
Market Cap
$17.23 million
Optionable
Optionable
Beta
1.05

Key Executives

  • Mr. Mark T. IwickiMr. Mark T. Iwicki (Age 56)
    Chairman & CEO
    Comp: $919.89k
  • Mr. Todd BazemoreMr. Todd Bazemore (Age 52)
    Pres & COO
    Comp: $671.58k
  • Dr. Kim Brazzell Ph.D. (Age 69)
    Head of R&D and Chief Medical Officer
    Comp: $645.19k
  • Dr. Justin Hanes Ph.D.
    Founder & Chair of the Scientific Advisory Board
  • Ms. Mary Reumuth CPAMs. Mary Reumuth CPA (Age 47)
    CPA, CFO & Treasurer
  • Ms. Jill S. Steier
    Exec. Director of Investor Relations & Corp. Communications
  • Mr. Eric L. Trachtenberg (Age 49)
    Gen. Counsel, Chief Compliance Officer & Corp. Sec.
  • Ms. Michele LaRussa (Age 52)
    Sr. VP of Regulatory Affairs & Quality Assurance
  • Mr. Vincent Kosewski (Age 59)
    Sr. VP of Manufacturing & Supply Chain Management
  • Mr. James Patnoe
    Sr. VP of Market Access, Commercial Operations & Pricing













KALA Stock - Frequently Asked Questions

Should I buy or sell Kala Pharmaceuticals stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last twelve months. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" KALA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KALA, but not buy additional shares or sell existing shares.
View KALA analyst ratings
or view top-rated stocks.

What is Kala Pharmaceuticals' stock price forecast for 2022?

3 Wall Street analysts have issued 1-year target prices for Kala Pharmaceuticals' shares. Their KALA share price forecasts range from $0.75 to $2.00. On average, they anticipate the company's stock price to reach $1.38 in the next twelve months. This suggests a possible upside of 443.9% from the stock's current price.
View analysts price targets for KALA
or view top-rated stocks among Wall Street analysts.

How have KALA shares performed in 2022?

Kala Pharmaceuticals' stock was trading at $0.6050 at the beginning of 2022. Since then, KALA stock has decreased by 58.2% and is now trading at $0.2528.
View the best growth stocks for 2022 here
.

When is Kala Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our KALA earnings forecast
.

How were Kala Pharmaceuticals' earnings last quarter?

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) issued its earnings results on Thursday, August, 11th. The company reported ($0.38) earnings per share for the quarter, beating analysts' consensus estimates of ($0.44) by $0.06. The business earned $2.10 million during the quarter, compared to the consensus estimate of $2.57 million. Kala Pharmaceuticals had a negative trailing twelve-month return on equity of 1,320.11% and a negative net margin of 1,628.91%.

When did Kala Pharmaceuticals' stock split?

Kala Pharmaceuticals's stock split on the morning of Friday, August 26th 2022. The 2-1 split was announced on Friday, August 26th 2022. The newly minted shares were distributed to shareholders after the closing bell on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What is Mark Iwicki's approval rating as Kala Pharmaceuticals' CEO?

1 employees have rated Kala Pharmaceuticals Chief Executive Officer Mark Iwicki on Glassdoor.com. Mark Iwicki has an approval rating of 100% among the company's employees. This puts Mark Iwicki in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Kala Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kala Pharmaceuticals investors own include Pfizer (PFE), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Micron Technology (MU), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Amarin (AMRN), Bristol-Myers Squibb (BMY), NVIDIA (NVDA) and AbbVie (ABBV).

When did Kala Pharmaceuticals IPO?

(KALA) raised $90 million in an IPO on Thursday, July 20th 2017. The company issued 6,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.

What is Kala Pharmaceuticals' stock symbol?

Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA."

Who are Kala Pharmaceuticals' major shareholders?

Kala Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Millennium Management LLC (0.79%), Renaissance Technologies LLC (0.49%), State Street Corp (0.36%), Goldman Sachs Group Inc. (0.33%), Vahanian & Associates Financial Planning Inc. (0.25%) and Integrated Wealth Concepts LLC (0.21%). Insiders that own company stock include Eric Trachtenberg, Hongming Chen, Mark T Iwicki, Mark T Iwicki, Mary Reumuth, Ra Capital Management, LP, Rajeev M Shah, Romulus K Brazzell and Todd Bazemore.
View institutional ownership trends
.

How do I buy shares of Kala Pharmaceuticals?

Shares of KALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kala Pharmaceuticals' stock price today?

One share of KALA stock can currently be purchased for approximately $0.25.

How much money does Kala Pharmaceuticals make?

Kala Pharmaceuticals (NASDAQ:KALA) has a market capitalization of $18.51 million and generates $11.24 million in revenue each year. The company earns $-142,600,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis.

How many employees does Kala Pharmaceuticals have?

The company employs 192 workers across the globe.

How can I contact Kala Pharmaceuticals?

Kala Pharmaceuticals' mailing address is 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02472. The official website for the company is www.kalarx.com. The company can be reached via phone at (781) 996-5252, via email at hannah.deresiewicz@sternir.com, or via fax at 781-642-0399.

This page (NASDAQ:KALA) was last updated on 9/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.